Why Clinical Trials Matter to HF Patient Care and Outcomes
On this episode, we’ll learn about clinical trials and research opportunities for heart failure patients, and why they matter to patient care and outcomes.
Listen below and subscribe: Apple Podcasts, Podcast Home
Host: Laura Poko, Director of Marketing and Communications, Heart Failure Society of America
Guests:
Cynthia Chauhan is a patient living with heart failure who is actively involved in patient advocacy and she serves on the HFSA Board of Directors as a patient advocate.
Melvin R. Echols, MD, FACC, Assistant Professor of Medicine at Morehouse School of Medicine in Atlanta, Georgia
Mona Fiuzat, PharmD, MS, Associate Professor of Medicine at Duke University and Senior Scientific Advisor at the FDA
Full Bios
Dr. Echols is an Assistant Professor of Medicine with Morehouse School of Medicine. His clinical and research endeavors are primarily focused on health equity for underrepresented heart failure populations.
Cynthia Chauhan is a patient with HFpEF and multiple comorbidities including pulmonary hypertension, stage 4 CKD and three kinds of arthritis with a history of breast and kidney cancers. Because HFpEF is currently untreatable, Chauhan regularly enrolls in clinical trials and practices focused self-care including regular exercise and a low sodium diet. Chauhan also participates in the development and monitoring of clinical trials as a patient representative on executive committees.